Evidence map›Paper›PMID 23915702›Full record

ArticleSkeletal muscle2013

Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice.

Nicholas Ieronimakis, Mario Pantoja, Aislinn L Hays, Timothy L Dosey, Junlin Qi, Karin A Fischer, Andrew N Hoofnagle, Martin Sadilek, Jeffrey S Chamberlain, Hannele Ruohola-Baker and 1 more

Open access · goldAbstract read
In one paragraph

Article in Skeletal muscle, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. S1P/S1P Receptor Signaling in Neuromuscolar Disorders.International journal of molecular sciences · 2019
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nicholas IeronimakisDepartment of Pathology, School of Medicine, University of Washington, Seattle, WA 98195, USA. hannele@u.washington.edu.
Mario Pantoja
Aislinn L Hays
Timothy L Dosey
Junlin Qi
Karin A Fischer
Andrew N Hoofnagle
Martin Sadilek
Jeffrey S Chamberlain
Hannele Ruohola-Baker
Morayma Reyes
University of Washington · US

Funding

Assembly of the Dystrophin-Glycoprotein ComplexR01AR044533 · NIAMS · UNIVERSITY OF WASHINGTON · PI CHAMBERLAIN, JEFFREY S · 1997 to 2021
$8.9M
MicroRNA Function in Human Embryonic Stem CellsR01GM083867 · NIGMS · UNIVERSITY OF WASHINGTON · PI RUOHOLA-BAKER, HANNELE · 2008 to 2011
$1.5M
Acquisition of Embryonic Stem Cell Metabolic Signature - Minority SupplementR01GM097372 · NIGMS · UNIVERSITY OF WASHINGTON · PI RUOHOLA-BAKER, HANNELE · 2011 to 2014
$1.3M
Generation of Wunen/LPP3-based therapy for muscular dystrophyRC1AR058520 · NIAMS · UNIVERSITY OF WASHINGTON · PI RUOHOLA-BAKER, HANNELE · 2009 to 2010
$928k
NIAMS NIH HHS R01 AR044533NIAMS NIH HHS RC1 AR058520NIGMS NIH HHS R01 GM083867NIGMS NIH HHS R01 GM097372
6 · The paper itself

Abstract

backgroundPresently, there is no effective treatment for the lethal muscle wasting disease Duchenne muscular dystrophy (DMD). Here we show that increased sphingosine-1-phoshate (S1P) through direct injection or via the administration of the small molecule 2-acetyl-4(5)-tetrahydroxybutyl imidazole (THI), an S1P lyase inhibitor, has beneficial effects in acutely injured dystrophic muscles of mdx mice.

methodsWe treated mdx mice with and without acute injury and characterized the histopathological and functional effects of increasing S1P levels. We also tested exogenous and direct administration of S1P on mdx muscles to examine the molecular pathways under which S1P promotes regeneration in dystrophic muscles.

resultsShort-term treatment with THI significantly increased muscle fiber size and extensor digitorum longus (EDL) muscle specific force in acutely injured mdx limb muscles. In addition, the accumulation of fibrosis and fat deposition, hallmarks of DMD pathology and impaired muscle regeneration, were lower in the injured muscles of THI-treated mdx mice. Furthermore, increased muscle force was observed in uninjured EDL muscles with a longer-term treatment of THI. Such regenerative effects were linked to the response of myogenic cells, since intramuscular injection of S1P increased the number of Myf5nlacz/+ positive myogenic cells and newly regenerated myofibers in injured mdx muscles. Intramuscular injection of biotinylated-S1P localized to muscle fibers, including newly regenerated fibers, which also stained positive for S1P receptor 1 (S1PR1). Importantly, plasma membrane and perinuclear localization of phosphorylated S1PR1 was observed in regenerating muscle fibers of mdx muscles. Intramuscular increases of S1P levels, S1PR1 and phosphorylated ribosomal protein S6 (P-rpS6), and elevated EDL muscle specific force, suggest S1P promoted the upregulation of anabolic pathways that mediate skeletal muscle mass and function.

conclusionsThese data show that S1P is beneficial for muscle regeneration and functional gain in dystrophic mice, and that THI, or other pharmacological agents that raise S1P levels systemically, may be developed into an effective treatment for improving muscle function and reducing the pathology of DMD.

Identifiers

PMID23915702
PMCPMC3750760
OpenAlexW2077995161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.